ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ENZY Enzymotec Ltd. - Ordinary Shares (delisted)

11.85
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Enzymotec Ltd. - Ordinary Shares (delisted) NASDAQ:ENZY NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 11.85 0.05 199,999.95 0 01:00:00

Acting CFO of Enzymatica appointed

24/03/2016 7:30am

GlobeNewswire


Bengt Jöndell has been appointed Acting CFO of Enzymatica with effect from 4 April. Johan Wennerholm, Enzymatica's current CFO, has decided to leave the company to take up an appointment as CEO of a company outside the Group. The recruitment process for a new CFO has begun. Johan Wennerholm will remain with the company for the next few months to facilitate the hand-over to Bengt Jöndell.

Bengt's most recent post was as CFO and Administrative Manager at BTJ Group AB. Before that, his appointments included Senior Financial Advisor at the med tech company, BoneSupport, CFO/Administrative Manager at Inpac, Business Controller at Pharmacia & Upjohn Consumer Healthcare, Pharmacia Consumer Pharma and Kabi Pharmacia Nicorette.

            "Bengt Jöndell has an excellent background for an Acting CFO, with 25 years' experience of finance, HR, IT and
management from international companies, part of that in pharmaceuticals," said Fredrik Lindberg, CEO of Enzymatica. Fredrik continued:
             
            "Johan Wennerholm has done an outstanding job at Enzymatica, including leading the listing process on Nasdaq First North. He has made a highly significant contribution to the company's progress in areas such as finance and administration. I wish him every success with his new challenges."

For more information, please contact:

Fredrik Lindberg, CEO, Enzymatica AB
Tel: 0708-86 53 70 | E-mail: fredrik.lindberg@enzymatica.com   

About Enzymatica AB
Enzymatica is a life science company who develops and sells medical device products against infectious-related diseases. Over a short period the company has developed a unique oral spray for colds, ColdZyme®, and launched it on six markets. The product has become one of the leading articles for colds in Swedish pharmacies. Enzymatica's strategy is to continue growing by strengthening its position in existing markets and to expand to more geographical markets through well-established partners. The company is headquartered in Lund, Sweden and is listed on Nasdaq First North. For more information, please visit www.enzymatica.com.   

Enzymatica's certified adviser is Erik Penser Bankaktiebolag.

Press Release (PDF)



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Enzymatica AB via Globenewswire

HUG#1997235

1 Year ENZYMOTEC LTD. Chart

1 Year ENZYMOTEC LTD. Chart

1 Month ENZYMOTEC LTD. Chart

1 Month ENZYMOTEC LTD. Chart

Your Recent History

Delayed Upgrade Clock